Skip to main content
Journal cover image

Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.

Publication ,  Journal Article
Singh, B; MahmoudianDehkordi, S; Voort, JLV; Han, X; Port, JD; Frye, MA; Kaddurah-Daouk, R; Mood Disorders Precision Medicine Consortium (MDPMC),
Published in: Psychiatry Res
August 2022

In this pilot study (N = 9), we highlight new insights gained on ketamine's mechanism of action where we have mapped biochemical processes that are affected within 40 min of intravenous ketamine exposure. Targeting acylcarnitines, we demonstrated rapid utilization of short-chain acylcarnitines within 40 min of ketamine treatment followed by restoration within 24 h; this change in short chain acylcarnitine with rapid-acting antidepressant treatment is consistent with previous work identifying similar change but at 8-weeks with slower-acting SSRI treatment. Using a non-targeted metabolomics platform, we defined broader effects of ketamine on lipid metabolism and identified changes in triglyceride that correlate with ketamine response. This study provides novel insights into ketamine's action and highlighting a possible role for mitochondrial function and energy metabolism in ketamine's mechanism of action.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Psychiatry Res

DOI

EISSN

1872-7123

Publication Date

August 2022

Volume

314

Start / End Page

114655

Location

Ireland

Related Subject Headings

  • Psychiatry
  • Pilot Projects
  • Ketamine
  • Humans
  • Depressive Disorder, Treatment-Resistant
  • Depression
  • Antidepressive Agents
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Singh, B., MahmoudianDehkordi, S., Voort, J. L. V., Han, X., Port, J. D., Frye, M. A., … Mood Disorders Precision Medicine Consortium (MDPMC), . (2022). Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res, 314, 114655. https://doi.org/10.1016/j.psychres.2022.114655
Singh, Balwinder, Siamak MahmoudianDehkordi, Jennifer L Vande Voort, Xianlin Han, John D. Port, Mark A. Frye, Rima Kaddurah-Daouk, and Rima Mood Disorders Precision Medicine Consortium (MDPMC). “Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.Psychiatry Res 314 (August 2022): 114655. https://doi.org/10.1016/j.psychres.2022.114655.
Singh B, MahmoudianDehkordi S, Voort JLV, Han X, Port JD, Frye MA, et al. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res. 2022 Aug;314:114655.
Singh, Balwinder, et al. “Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study.Psychiatry Res, vol. 314, Aug. 2022, p. 114655. Pubmed, doi:10.1016/j.psychres.2022.114655.
Singh B, MahmoudianDehkordi S, Voort JLV, Han X, Port JD, Frye MA, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium (MDPMC). Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res. 2022 Aug;314:114655.
Journal cover image

Published In

Psychiatry Res

DOI

EISSN

1872-7123

Publication Date

August 2022

Volume

314

Start / End Page

114655

Location

Ireland

Related Subject Headings

  • Psychiatry
  • Pilot Projects
  • Ketamine
  • Humans
  • Depressive Disorder, Treatment-Resistant
  • Depression
  • Antidepressive Agents
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences